HUMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Humacyte Inc (HUMA) is not a strong buy at the moment for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. While the stock shows some potential for short-term gains, the lack of positive financial performance, weak analyst sentiment, and absence of significant catalysts make it unsuitable for long-term investment at this time.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 45.65, showing no overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. The stock is trading near its pivot level of 1.144, with support at 1.06 and resistance at 1.228.
NULL identified. There is no recent news or significant trading activity by insiders, hedge funds, or Congress. The options market shows some bullish sentiment, but it is not enough to outweigh other factors.
Financial performance is weak, with a significant drop in net income (-55.33% YoY) and EPS (-66.67% YoY). Analyst sentiment has also weakened, with a reduced price target from $11 to $10 due to recent financing activities. No recent news or event-driven catalysts to drive the stock higher.
In Q3 2025, revenue remained flat at $753,000 (0.00% YoY growth), while net income dropped significantly to -$17.51M (-55.33% YoY). EPS also declined to -0.11 (-66.67% YoY). Gross margin improved slightly to 65.47%, but this is overshadowed by the poor profitability metrics.
Benchmark has lowered the price target from $11 to $10, maintaining a Buy rating. However, this downgrade reflects weaker sentiment due to recent financing activities.
